Labcorp issues long-term outlook through 2029 and reaffirms full-year 2026 guidance
The laboratory services provider projected compound annual revenue growth between 5% and 8% through 2029 at its investor day.
Labcorp Holdings Inc. (LH) hosted its 2026 Investor Day on Wednesday, where the company outlined its long-term financial outlook through 2029 and reaffirmed its full-year 2026 guidance. The company detailed expectations for sustained revenue growth, margin expansion, and cash flow generation driven by specialty testing, strategic partnerships, and advanced technology.
Key takeaways
- Reaffirmed full-year 2026 enterprise revenue guidance between $14,710 million and $14,827 million.
- Projected long-term compound annual revenue growth of 5% to 8% from 2026 through 2029.
- Targeted compound annual adjusted earnings per share growth of 8.5% to 11.5% through 2029.
- Expected adjusted operating margin expansion between 75 and 150 basis points by the end of 2029.
Long-term financial outlook through 2029
According to a regulatory filing, the company's outlook through 2029 includes organic revenue growth between 3.5% and 5.5% and acquisition revenue contribution between 1.5% and 2.5%. Diagnostics revenue is expected to grow at a compound annual rate between 2.5% and 4.5%, while Biopharma Laboratory Services revenue is projected to grow between 4.0% and 7.0%. Free cash flow growth is expected to remain in line with adjusted earnings growth.
"Labcorp has never been more relevant than it is today," said Adam Schechter, Chairman and CEO of Labcorp, in a statement. "The healthcare landscape is being transformed by scientific innovation, personalized medicine and consumer-directed care, and the strengths of Labcorp will help shape the future of healthcare."
Reaffirmed 2026 guidance details
The company maintained its previously issued full-year 2026 guidance figures. Adjusted earnings per share are expected to range from $18.10 to $18.55, with free cash flow anticipated between $1,240 million and $1,360 million. Diagnostics Laboratories revenue is guided between $11,450 million and $11,532 million, while Biopharma Laboratory Services revenue is guided between $3,269 million and $3,300 million.
"Our confidence in this outlook is grounded in a proven record of delivering on our commitments and a disciplined value creation framework that converts growth into earnings, cash flow and shareholder returns," said Julia Wang, Executive Vice President and Chief Financial Officer.
Why it matters
The disclosures provide investors with visibility into the company's multi-year operating trajectory, capital deployment strategy, and margin expansion targets. The outlook incorporates assumptions regarding foreign exchange rates as of June 30, 2026, anticipated capital allocation including share repurchases and dividends, and potential return of the Clinical Laboratory Fee Schedule data reporting under the Protecting Access to Medicare Act, known as PAMA.
By the numbers
| Metric | Value | Source |
|---|---|---|
| 2026 Enterprise Revenue Guidance | $14,710 million to $14,827 million | Press Release |
| 2026 Diagnostics Laboratories Guidance | $11,450 million to $11,532 million | Press Release |
| 2026 Biopharma Laboratory Services Guidance | $3,269 million to $3,300 million | Press Release |
| 2026 Adjusted EPS Guidance | $18.10 to $18.55 | Press Release |
| 2026 Free Cash Flow Guidance | $1,240 million to $1,360 million | Press Release |
| 2026-2029 Revenue CAGR Outlook | 5.0% to 8.0% | Press Release |
| 2026-2029 Adjusted EPS CAGR Outlook | 8.5% to 11.5% | Press Release |
Capital deployment and operating assumptions
The company outlined plans for ongoing capital allocation, projecting operating cash flow between $6.3 billion and $7.2 billion for the 2027 through 2029 period. Capital expenditures are anticipated to run at approximately 4% of revenue. Dividends are targeted within a range of 15% to 20% of adjusted earnings, and share repurchases will serve as a strategic lever to cover share dilution at a minimum while maintaining a gross debt to trailing twelve months adjusted EBITDA financial leverage ratio between 2.5x and 3.0x.